Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients
NCT ID: NCT00349388
Last Updated: 2019-01-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
1 participants
INTERVENTIONAL
2006-07-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis
NCT00343850
Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
NCT02093663
A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.
NCT00254618
The Colitis Once Daily Asacol Study
NCT00708656
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis
NCT01004185
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Asacol once a day dosing
Asacol total dose in mg/kg given once a day
Asacol
Asacol is given once a day versus twice or three times a day
Asacol BID/TID dosing
Asacol total dose split BID or TID
Asacol
Asacol is given once a day versus twice or three times a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Asacol
Asacol is given once a day versus twice or three times a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to swallow tablets, and
* Biopsy proven ulcerative colitis
Exclusion Criteria
* Use of rectal medications
6 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Procter and Gamble
INDUSTRY
Annette Langseder
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Annette Langseder
Joel Rosh, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joel Rosh, MD
Role: PRINCIPAL_INVESTIGATOR
Atlantic Health System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Morristown Memorial Hospital/Goyerb Children's Hospital
Morristown, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R05-11-010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.